Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ER negative + HER-2 negative

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

PIK3CA mutation + HR positive (16)

PIK3CA mutation + ER positive (10)

HER-2 amplification + RAS wild-type + BRAF wild-type (9)

ESR1 mutation + HR positive (6)

HER-2 positive + HER-2 amplification (4)

RAS wild-type + HER-2 positive (4)

ESR1 wild-type + HR positive (4)

HER-2 amplification + KRAS G12D (3)

BRCA1 mutation + HR positive (3)

BRCA2 mutation + HR positive (3)

ER positive + PIK3CA H1047R (3)

FGFR1 amplification + HR positive (3)

HR positive + BRCA2 mutation (3)

HR-positive + PIK3CA wild-type (3)

PIK3CA exon 20 mutation + HR positive (3)

BRAF wild-type + HER-2 positive (2)

BRCA1 mutation + HER-2 negative (2)

BRCA2 mutation + HER-2 negative (2)

HER-2 S310F + HER-2 amplification (2)

HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K (2)

HER-2 amplification + HER-2 L755S (2)

HER-2 amplification + PD-L1 expression (2)

HER-2 amplification + RAS wild-type (2)

HER-2 expression + HER-2 D769H (2)

HER-2 expression + HER-2 L869R (2)

HER-2 expression + HER-2 amplification (2)

HER-2 expression + TMB-H (2)

RAS wild-type + BRAF wild-type + HER-2 positive (2)

TMB-H + HER-2 positive (2)

AKT1 E17K + HR positive (2)

AKT1 mutation + ER positive (2)

AKT1 mutation + HR positive (2)

ER Y537S + ER positive (2)

ER positive + TP53 mutation (2)

HR negative + BRCA1 mutation (2)

HR negative + BRCA2 mutation (2)

HR positive + BRCA1 mutation (2)

HR positive + MYC amplification (2)

HR positive + TP53 mutation (2)

PIK3CA mutation + ER negative (2)

PTEN deletion + ER positive (2)

AR positive + HER-2 amplification (1)

BRCA1 mutation + HER-2 negative + ER positive + PGR positive (1)

CD74-NRG1 fusion + EGFR mutation + HER-2 mutation (1)

EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)

EGFR T790M + HER-2 amplification (1)

EGFR exon 19 deletion + EGFR T790M + EGFR C797S + HER-2 amplification (1)

ER negative + HER-2 positive + PGR positive + PIK3CA mutation (1)

ER positive + HER-2 D769H + HER-2 V777L (1)

ERBB2 G778A + CCNE1 amplification (1)

ERBB3 mutation + HER-2 amplification (1)

ERBB4 mutation + HER-2 positive (1)

HER-2 amplification + AXL expression (1)

HER-2 amplification + BRAF wild-type (1)

HER-2 amplification + CCNE1 expression (1)

HER-2 amplification + EGFR mutation (1)

HER-2 amplification + ER positive + PGR negative (1)

HER-2 amplification + HER-2 R157W (1)

HER-2 amplification + HER-2 mutation (1)

HER-2 amplification + KRAS exon 2 wild-type (1)

HER-2 amplification + KRAS wild-type (1)

HER-2 elevation (1)

HER-2 elevation + TMB-H (1)

HER-2 elevation + TMB-L (1)

HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)

HER-2 mutation + HER-2 positive (1)

HER-2 mutation + TMB-H (1)

HER-2 overexpression + CCNE1 amplification (1)

HER-2 overexpression + HER-2 amplification (1)

HER-2 overexpression + KRAS G12C (1)

HER-2 overexpression + KRAS wild-type (1)

HER-2 overexpression + PTEN deletion (1)

HER-2 overexpression + RAS wild-type (1)

HER-2 positive + APC mutation (1)

HER-2 positive + GATA6 amplification (1)

HER-2 positive + MYC amplification (1)

HER-2 positive + TP53 mutation (1)

HER-2 underexpression + CCNE1 amplification (1)

HR positive + HER-2 amplification (1)

HR positive + HER-2 mutation (1)

KRAS G12D + HER-2 amplification + TMB-H (1)

KRAS mutation + HER-2 positive (1)

MSI-H + HER-2 amplification (1)

MSI-H/dMMR + HER-2 mutation (1)

NF1 mutation + HER-2 positive (1)

PD-L1 overexpression + HER-2 exon 20 insertion (1)

PIK3C3 mutation + HER-2 positive (1)

PIK3CA H1047R + HER-2 amplification (1)

PIK3CA mutation + HER-2 amplification (1)

PIK3CA mutation + HER-2 positive (1)

PIK3CA mutation + HR positive + HER-2 negative (1)

PIK3R1 mutation + HER-2 positive (1)

POLE E790Q + ERBB2 amplification + TMB-H (1)

RAS wild-type + HER-2 amplification (1)

RAS wild-type + HER-2 overexpression (1)

STAT6 deletion + HER-2 overexpression (1)

AKT1 mutation + ER negative (1)

BRCA2 mutation + ER positive (1)

BRCA2 mutation + ER positive + PGR positive (1)

CCND1 mutation + HR positive (1)

CCND2 mutation + HR positive (1)

CCNE1 overexpression + PIK3CA muattion + ER positive (1)

CCNE2 overexpression + PIK3CA mutation + ER positive (1)

CDK4 mutation + HR positive (1)

CDKN1B mutation + HR positive (1)

EGFR mutation + ER positive (1)

ER D538G + ER positive (1)

ER E380Q + ER positive (1)

ER L536H + ER D538G + CCND1 amplification (1)

ER Y537N + ER positive (1)

ER positive + ESR1 mutation + CCND1 amplification (1)

ER positive + ESR1 mutation + FGFR1 amplification (1)

ER positive + ESR1 mutation + PIK3CA mutation (1)

ER positive + ESR1 mutation + TP53 mutation (1)

ER positive + FGFR1 amplification (1)

ER positive + FGFR3 amplification (1)

ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H (1)

ER positive + ZNF217 overexpression (1)

ER underexpression + ER Y537S (1)

ERBB4 H809G + ER positive (1)

ESR1 mutation + PIK3CA mutation + HR positive (1)

FGF19 amplification + ER positive (1)

FGF3 amplification + ER positive (1)

FGF4 amplification + ER positive (1)

FOXA1 expression + ER positive (1)

HR negative + EGFR amplification (1)

HR positive + APOBEC signature (1)

HR positive + AURKA amplification (1)

HR positive + AURKA mutation (1)

HR positive + BRAF V600E (1)

HR positive + BRCA1 mutation + PALB2 mutation (1)

HR positive + BRCA2 mutation + PALB2 mutation (1)

HR positive + BRIP1 amplification (1)

HR positive + CCND1 amplification (1)

HR positive + MYC mutation (1)

HR positive + PIK3CA exon 10 mutation (1)

HR positive + PTEN deletion (1)

HR positive + RAD51C amplification (1)

HR positive + RB1 mutation (1)

HR positive + TMB-H (1)

HR positive + TMB-L (1)

High HDAC6 score + HR positive (1)

KRAS mutation + CDK9 overexpression + HR positive (1)

KRAS mutation + ER expression (1)

KRAS mutation + HR positive (1)

MTOR mutation + HR positive (1)

MYC mutation + ER positive (1)

PIK3CA E542K + HR positive (1)

PIK3CA amplification + PIK3CA mutation + HR positive (1)

PIK3CA exon 7 mutation + HR positive (1)

PIK3CA exon 9 mutation + HR positive (1)

PIK3CA mutation + ESR1 wild-type (1)

PIK3CA wild-type+ ESR1 wild-type (1)

PTEN mutation + HR positive (1)

TP53 wild-type + ER positive (1)

ER negative + HER-2 positive + PIK3CA H1047R (0)

ER positive + HER-2 negative + ER mutation (0)

HER-2 amplification + KRAS G12C (0)

HER-2 exon 20 mutation + HER-2 amplification (0)

HER-2 positive + FGFR1 amplification (0)

HR positive + HER-2 negative + TMB-L (0)

PIK3CA E453K + HER-2 positive (0)

PIK3CA E542K + HER-2 positive (0)

PIK3CA E542Q + HER-2 positive (0)

PIK3CA H1047L + HER-2 positive (0)

PIK3CA H1047R + HER-2 positive (0)

PIK3CA N345K + HER-2 positive (0)

PIK3CA amplification + HER-2 positive (0)

AKT1 E17K + CTNNB1 G34R + ER Y537S + MSI-H (0)

ER positive + BRCA1 mutation (0)

ER positive + BRCA2 mutation (0)

PIK3CA mutation + ER negative + PGR positive (0)

PIK3CA mutation + HR positive (16)

PIK3CA mutation + ER positive (10)

HER-2 amplification + RAS wild-type + BRAF wild-type (9)

ESR1 mutation + HR positive (6)

HER-2 positive + HER-2 amplification (4)

RAS wild-type + HER-2 positive (4)

ESR1 wild-type + HR positive (4)

HER-2 amplification + KRAS G12D (3)

BRCA1 mutation + HR positive (3)

BRCA2 mutation + HR positive (3)

ER positive + PIK3CA H1047R (3)

FGFR1 amplification + HR positive (3)

HR positive + BRCA2 mutation (3)

HR-positive + PIK3CA wild-type (3)

PIK3CA exon 20 mutation + HR positive (3)

BRAF wild-type + HER-2 positive (2)

BRCA1 mutation + HER-2 negative (2)

BRCA2 mutation + HER-2 negative (2)

HER-2 S310F + HER-2 amplification (2)

HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K (2)

HER-2 amplification + HER-2 L755S (2)

HER-2 amplification + PD-L1 expression (2)

HER-2 amplification + RAS wild-type (2)

HER-2 expression + HER-2 D769H (2)

HER-2 expression + HER-2 L869R (2)

HER-2 expression + HER-2 amplification (2)

HER-2 expression + TMB-H (2)

RAS wild-type + BRAF wild-type + HER-2 positive (2)

TMB-H + HER-2 positive (2)

AKT1 E17K + HR positive (2)

AKT1 mutation + ER positive (2)

AKT1 mutation + HR positive (2)

ER Y537S + ER positive (2)

ER positive + TP53 mutation (2)

HR negative + BRCA1 mutation (2)

HR negative + BRCA2 mutation (2)

HR positive + BRCA1 mutation (2)

HR positive + MYC amplification (2)

HR positive + TP53 mutation (2)

PIK3CA mutation + ER negative (2)

PTEN deletion + ER positive (2)

AR positive + HER-2 amplification (1)

BRCA1 mutation + HER-2 negative + ER positive + PGR positive (1)

CD74-NRG1 fusion + EGFR mutation + HER-2 mutation (1)

EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)

EGFR T790M + HER-2 amplification (1)

EGFR exon 19 deletion + EGFR T790M + EGFR C797S + HER-2 amplification (1)

ER negative + HER-2 positive + PGR positive + PIK3CA mutation (1)

ER positive + HER-2 D769H + HER-2 V777L (1)

ERBB2 G778A + CCNE1 amplification (1)

ERBB3 mutation + HER-2 amplification (1)

ERBB4 mutation + HER-2 positive (1)

HER-2 amplification + AXL expression (1)

HER-2 amplification + BRAF wild-type (1)

HER-2 amplification + CCNE1 expression (1)

HER-2 amplification + EGFR mutation (1)

HER-2 amplification + ER positive + PGR negative (1)

HER-2 amplification + HER-2 R157W (1)

HER-2 amplification + HER-2 mutation (1)

HER-2 amplification + KRAS exon 2 wild-type (1)

HER-2 amplification + KRAS wild-type (1)

HER-2 elevation (1)

HER-2 elevation + TMB-H (1)

HER-2 elevation + TMB-L (1)

HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)

HER-2 mutation + HER-2 positive (1)

HER-2 mutation + TMB-H (1)

HER-2 overexpression + CCNE1 amplification (1)

HER-2 overexpression + HER-2 amplification (1)

HER-2 overexpression + KRAS G12C (1)

HER-2 overexpression + KRAS wild-type (1)

HER-2 overexpression + PTEN deletion (1)

HER-2 overexpression + RAS wild-type (1)

HER-2 positive + APC mutation (1)

HER-2 positive + GATA6 amplification (1)

HER-2 positive + MYC amplification (1)

HER-2 positive + TP53 mutation (1)

HER-2 underexpression + CCNE1 amplification (1)

HR positive + HER-2 amplification (1)

HR positive + HER-2 mutation (1)

KRAS G12D + HER-2 amplification + TMB-H (1)

KRAS mutation + HER-2 positive (1)

MSI-H + HER-2 amplification (1)

MSI-H/dMMR + HER-2 mutation (1)

NF1 mutation + HER-2 positive (1)

PD-L1 overexpression + HER-2 exon 20 insertion (1)

PIK3C3 mutation + HER-2 positive (1)

PIK3CA H1047R + HER-2 amplification (1)

PIK3CA mutation + HER-2 amplification (1)

PIK3CA mutation + HER-2 positive (1)

PIK3CA mutation + HR positive + HER-2 negative (1)

PIK3R1 mutation + HER-2 positive (1)

POLE E790Q + ERBB2 amplification + TMB-H (1)

RAS wild-type + HER-2 amplification (1)

RAS wild-type + HER-2 overexpression (1)

STAT6 deletion + HER-2 overexpression (1)

AKT1 mutation + ER negative (1)

BRCA2 mutation + ER positive (1)

BRCA2 mutation + ER positive + PGR positive (1)

CCND1 mutation + HR positive (1)

CCND2 mutation + HR positive (1)

CCNE1 overexpression + PIK3CA muattion + ER positive (1)

CCNE2 overexpression + PIK3CA mutation + ER positive (1)

CDK4 mutation + HR positive (1)

CDKN1B mutation + HR positive (1)

EGFR mutation + ER positive (1)

ER D538G + ER positive (1)

ER E380Q + ER positive (1)

ER L536H + ER D538G + CCND1 amplification (1)

ER Y537N + ER positive (1)

ER positive + ESR1 mutation + CCND1 amplification (1)

ER positive + ESR1 mutation + FGFR1 amplification (1)

ER positive + ESR1 mutation + PIK3CA mutation (1)

ER positive + ESR1 mutation + TP53 mutation (1)

ER positive + FGFR1 amplification (1)

ER positive + FGFR3 amplification (1)

ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H (1)

ER positive + ZNF217 overexpression (1)

ER underexpression + ER Y537S (1)

ERBB4 H809G + ER positive (1)

ESR1 mutation + PIK3CA mutation + HR positive (1)

FGF19 amplification + ER positive (1)

FGF3 amplification + ER positive (1)

FGF4 amplification + ER positive (1)

FOXA1 expression + ER positive (1)

HR negative + EGFR amplification (1)

HR positive + APOBEC signature (1)

HR positive + AURKA amplification (1)

HR positive + AURKA mutation (1)

HR positive + BRAF V600E (1)

HR positive + BRCA1 mutation + PALB2 mutation (1)

HR positive + BRCA2 mutation + PALB2 mutation (1)

HR positive + BRIP1 amplification (1)

HR positive + CCND1 amplification (1)

HR positive + MYC mutation (1)

HR positive + PIK3CA exon 10 mutation (1)

HR positive + PTEN deletion (1)

HR positive + RAD51C amplification (1)

HR positive + RB1 mutation (1)

HR positive + TMB-H (1)

HR positive + TMB-L (1)

High HDAC6 score + HR positive (1)

KRAS mutation + CDK9 overexpression + HR positive (1)

KRAS mutation + ER expression (1)

KRAS mutation + HR positive (1)

MTOR mutation + HR positive (1)

MYC mutation + ER positive (1)

PIK3CA E542K + HR positive (1)

PIK3CA amplification + PIK3CA mutation + HR positive (1)

PIK3CA exon 7 mutation + HR positive (1)

PIK3CA exon 9 mutation + HR positive (1)

PIK3CA mutation + ESR1 wild-type (1)

PIK3CA wild-type+ ESR1 wild-type (1)

PTEN mutation + HR positive (1)

TP53 wild-type + ER positive (1)

ER negative + HER-2 positive + PIK3CA H1047R (0)

ER positive + HER-2 negative + ER mutation (0)

HER-2 amplification + KRAS G12C (0)

HER-2 exon 20 mutation + HER-2 amplification (0)

HER-2 positive + FGFR1 amplification (0)

HR positive + HER-2 negative + TMB-L (0)

PIK3CA E453K + HER-2 positive (0)

PIK3CA E542K + HER-2 positive (0)

PIK3CA E542Q + HER-2 positive (0)

PIK3CA H1047L + HER-2 positive (0)

PIK3CA H1047R + HER-2 positive (0)

PIK3CA N345K + HER-2 positive (0)

PIK3CA amplification + HER-2 positive (0)

AKT1 E17K + CTNNB1 G34R + ER Y537S + MSI-H (0)

ER positive + BRCA1 mutation (0)

ER positive + BRCA2 mutation (0)

PIK3CA mutation + ER negative + PGR positive (0)

›

2years

Prognosis and effectiveness of chemotherapy for medullary breast carcinoma. (PubMed, Breast Cancer Res Treat)

In ER-negative and HER2-negative MedBC, the risk of recurrence and death was significantly lower than that of IDC, about half. Postoperative chemotherapy reduced recurrence and mortality. ER-positive and HER2-negative MedBC may have a lower risk of recurrence compared to IDC.

2 years ago

Journal

|

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)

|

ER positive • HER-2 negative • ER negative • ER positive + HER-2 negative • ER negative + HER-2 negative

over2years

CADENCE: Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer (clinicaltrials.gov)

P2, N=25, Active, not recruiting, Mothaffar Rimawi | Trial completion date: Sep 2021 --> Sep 2024

over 2 years ago

Trial completion date

|

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

|

HER-2 negative • ER negative • PGR positive • ER negative + HER-2 negative

|

carboplatin • docetaxel

over2years

The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer. (PubMed, Clin J Oncol Nurs)

Patients with ER-positive MBC had greater odds of receiving quality end-of-life care than those with ER-negative MBC. HER2 status was not associated with differences in the quality of end-of-life care.

over 2 years ago

Journal

|

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)

|

ER positive • HER-2 negative • ER negative • ER negative + HER-2 negative